TRAVERE THERAPEUTICS, INC. Current Federal Tax Expense (Benefit)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Current Federal Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-19
- TRAVERE THERAPEUTICS, INC. current federal tax expense (benefit) for the quarter ending 2015-03-31 was $39.90M.
- TRAVERE THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2025 was $0.00.
- TRAVERE THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2024 was $0.00.
- TRAVERE THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2023 was $0.00.
- TRAVERE THERAPEUTICS, INC. current federal tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Current Federal Tax Expense (Benefit) 3 month | Current Federal Tax Expense (Benefit) 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-19 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-19 | |
| 2023-12-31 | $0.00 10-K · filed 2026-02-19 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-21 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-20 | |
| 2020-12-31 | -$19.44M 10-K · filed 2023-02-23 | |
| 2019-12-31 | -$319.00K 10-K · filed 2022-02-24 | |
| 2018-12-31 | $698.00K 10-K · filed 2021-03-01 | |
| 2017-12-31 | $6.99M 10-K · filed 2020-02-24 | |
| 2016-12-31 | $13.14M 10-K · filed 2019-02-26 | |
| 2015-12-31 | $2.09M 10-K · filed 2018-07-06 | |
| 2015-03-31 | $39.90M 10-Q · filed 2015-05-11 | |
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 | |
| 2013-12-31 | $0.00 10-K · filed 2016-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |